Medexus Pharmaceuticals (TSE:MDP) Stock Price Down 13.2% – Time to Sell?

Medexus Pharmaceuticals Inc. (TSE:MDP)’s stock price traded down 13.2% during trading on Thursday . The company traded as low as C$3.25 and last traded at C$3.29. 114,178 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 177,975 shares. The stock had previously closed at C$3.79.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research note on Thursday, January 30th. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research note on Wednesday, January 8th. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Ventum Financial lifted their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Finally, Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two research analysts have rated the stock with a buy rating and five have issued a strong buy rating to the stock. According to MarketBeat.com, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Price Performance

The stock has a fifty day moving average price of C$3.52 and a two-hundred day moving average price of C$2.82. The company has a market cap of C$73.84 million, a P/E ratio of 60.20 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.